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Abstract: Inducible genetically defined mouse models of cancer uniquely facilitate the investigation 
of early events in cancer progression, however, there are valid concerns about the ability of such 
models to faithfully recapitulate human disease. We developed an inducible mouse model of 
progressive lung adenocarcinoma (LuAd) that combines sporadic activation of oncogenic KRasG12D 
with modest overexpression of c-MYC (KM model). Histological examination revealed a highly 
reproducible spontaneous transition from low-grade adenocarcinoma to locally invasive 
adenocarcinoma within 6 weeks of oncogene activation. Laser-capture microdissection coupled 
with RNA-SEQ (ribonucleic acid sequencing) was employed to determine transcriptional changes 
associated with tumour progression. Upregulated genes were triaged for relevance to human LuAd 
using datasets from Oncomine and cBioportal. Selected genes were validated by RNAi screening in 
human lung cancer cell lines and examined for association with lung cancer patient overall survival 
using KMplot.com. Depletion of progression-associated genes resulted in pronounced viability 
and/or cell migration defects in human lung cancer cells. Progression-associated genes moreover 
exhibited strong associations with overall survival, specifically in human lung adenocarcinoma, but 
not in squamous cell carcinoma. The KM mouse model faithfully recapitulates key molecular events 
in human adenocarcinoma of the lung and is a useful tool for mechanistic interrogation of KRAS-
driven LuAd progression. 
Keywords: lung adenocarcinoma; KRAS; MYC; ERBB; Mouse models of cancer; RNA-SEQ 
 
1. Introduction 
Genetically engineered mouse models (GEMMs) are powerful tools for understanding the roles 
of specific oncogenes and tumour suppressors in cancer development and progression. The term 
“GEMM” spans a broad spectrum of design strategies, ranging from constitutive whole-body 
deletion of tumour suppressors or overexpression of oncogenes from tissue-specific promoter 
fragments, the latter typically resulting in artificially high levels of oncogene expression in every cell 
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of a given tissue, to more refined conditional allelic models that allow for sporadic activation/deletion 
of the target allele in a temporally controlled manner [1,2]. For even the most elegantly designed 
GEMMs. However, there are valid concerns about the ability of such models to faithfully recapitulate 
the molecular evolution and features of human cancer [3]. This is particularly true for cancers, such 
as lung cancer, that arise primarily from exposure to environmental toxins. Given that GEMMs are 
increasingly used for pre-clinical testing of novel treatment strategies it is vitally important to 
interrogate their suitability for this role [4]. 
Development of the lsl-KRasG12D allele, in which a single-nucleotide altered coding exon of KRas 
was inserted into the endogenous KRas locus downstream of a CRE-deletable lox-stop-lox cassette, 
represented a watershed moment in the progress of GEMM development [5]. Aside from the 
requirement for exposure to CRE recombinase, expression of this allele is entirely physiological, 
marking a major departure from previous transgenic models that typically relied on pronounced 
overexpression of oncogenes from strong tissue-restricted promoters [6]. An oncogene that is 
overexpressed as well as mutated will elicit a much stronger signal than one that is merely mutated, 
with profound implications for phenotypic evolution [7]. Given that KRAS is much more frequently 
mutated without overexpression than with [8], the lsl-KRasG12D allele better reflects the expression of 
activated KRAS in human disease than would an overt overexpression allele. Perhaps unsurprisingly, 
this allele emerged to be relatively inefficient in driving late stage cancer but very effective in driving 
incipient early stage disease [5]. The modest oncogenic output of lsl-KRasG12D, however, turns out to 
be its principle strength, allowing for the investigation of spontaneous tumour progression from pre-
cancerous lesions. Accordingly, combination of this allele with additional oncogenes or tumour 
suppressors readily drives progression of incipient tumours [9–11]. 
By comparison, modeling the oncogenic output of MYC deregulation at a level that reflects 
incipient human cancer is more challenging. Although MYC expression is typically quite high in late-
stage human cancers, pronounced overexpression of MYC in normal tissue immediately elicits an 
apoptotic response, eliminating the offending cells [12–14]. The prior or simultaneously inactivation 
of apoptosis is typically a prerequisite for tumour initiation by high levels of MYC [15,16]. Insertion 
of a conditional and acutely inducible allele of c-MYC into the Rosa26 locus led to the serendipitous 
discovery of a proliferation competent level of MYC expression below the threshold required to drive 
apoptosis [17]: Rosa26-lsl-MycERTam mice express a Tamoxifen-dependent allele of the c-MYC 
oncogene fused in-frame to a minimal ligand-binding domain of human estrogen receptor, the latter 
modified to prevent activation by circulating estrogen [18]. Functional characterization of this allele 
demonstrated expression of MycERTam in the near-physiological range, relative to endogenously 
expressed c-Myc. Importantly, this level of expression sufficed to drive ectopic proliferation in all 
adult organs examined, without triggering widespread MYC-dependent apoptosis [17]. The 
implication of this observation is that modest MYC overexpression may, by virtue of evading intrinsic 
tumour suppression, exhibit enhanced tumour promoting activity compared with higher levels that 
overtly trigger apoptosis [19,20]. The sustained activity of MycERTam, however requires continuous 
administration of the synthetic ligand Tamoxifen, which exerts both agonist and antagonist activity 
on cells expressing the endogenous estrogen receptor, potentially impacting on MYC-driven 
phenotypes [21]. We, therefore, re-engineered the allele without the ER moiety to retain the low level 
of expression afforded by the Rosa26 locus and the CRE-dependence of expression, but to liberate 
MYC’s transcriptional activity from its dependence upon Tamoxifen (Figure S1). By combining the 
Rosa26-DM.lsl-MYC allele with lsl-KRasG12D, we aimed to model tumour evolution in an important 
subset of human non-small cell lung cancers. Here, we show accelerated development of low-grade 
adenocarcinomas that spontaneously progress to locally invasive disease. Transcriptomic analysis of 
spontaneously progressing tumours identified a gene expression signature of clear relevance for 
human lung adenocarcinoma.  
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2. Results 
2.1. MYC Accelerates KRasG12D-Driven LuAd Development 
Analysis of the TCGA (the cancer genome atlas) pan-cancer cohort of lung adenocarcinoma 
(LuAd) revealed amplification and/or overexpression of c-MYC in up to 20% of LuAd and a 
significant enrichment for MYC overexpression in KRAS mutant tumours (p = 0.025) (Figure 1A and 
S2). We used replication defective recombinant adenoviral delivery of CRE recombinase (Ad-CRE), 
administered by intranasal inhalation, to sporadically activate expression of transgenic MYC in the 
lungs of heterozygous Rosa26DM.lsl-MYC/+ (M) and homozygous Rosa26DM.lsl-MYC/lsl-MYC (M2) mice. Acute 
ectopic proliferation of airway epithelium, detected by BrdU incorporation 3 days after allele 
activation, was only detectable in homozygous mice (Figure 1B). No tumours could be detected in 
Ad-CRE induced M or M2 mice housed for up to 1 year after induction [22]. We, therefore, asked if 
Rosa26-driven MYC could cooperate with endogenously expressed active KRas to accelerate lung 
tumour development. Comparison of the lung tumour burden in Ad-CRE induced lsl-KRasG12D/+ (K), 
lsl-KRasG12D/+; Rosa26DM.lsl-MYC/+ (KM), and lsl-KRasG12D/+; Rosa26DM.lsl-MYC/lsl-MYC (KM2), mice at 6 weeks 
post induction (PI) revealed a dramatic, MYC-dose dependent, increase in the percentage of lung 
area occupied by tumours (Figure 1C). Histopathological analysis of KM2 tumours at 2, 4, and 6 weeks 
showed uniform progression of all incipient KM2 tumours to low-grade (non-invasive) 
adenocarcinoma in situ (Figure 1D), as previously defined [23]. This contrasts with KRasG12D/+-only 
lesions that fail to progress beyond atypical adenomatous hyperplasia within this time (Figure 1E) 
[5]. 
2.2.A Transcriptomic Signature of KRAS LuAd Tumour Progression 
As we recently reported [24], KM2 tumours sporadically progress to a higher-grade disease 
characterized by increased morphologic heterogeneity and sharply increased phosphorylation of 
Erk1/2, downstream of KRAS (Figure S3). We used laser-capture microdissection to collect such p-
ErkHI tumour regions, along with matching p-ErkLO regions from the same tumours, and RNA-SEQ 
analysis to determine changes in gene expression associated with progression of KM2 LuAd [24]. 
Across tumours from four mice we detected 1396 genes with significantly altered expression. To 
establish an expression signature of general relevance to human cancer irrespective of KRAS status, 
we used an arbitrary cutoff of 2.5X increased expression and evidence of overexpression and/or 
amplification from human LuAd datasets [25–27] available via Oncomine and cBioportal to stratify 
significantly upregulated genes, yielding a list of 52 genes (Table 1). This list notably includes 
EGFR/ERBB-family ligands Ereg and Areg, Wnt pathway constituents Sox9 and Porcn, nutrient 
transporters Slc2a1 and Slc38a1, and glycolytic enzymes Gapdh and Pgk1, the latter four suggestive of 
increased metabolic demand during LuAd progression. 
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Figure 1. MYC accelerates KRasG12D-driven lung adenocarcinoma (LuAd) development. (A) 
Frequency of mutation, copy number, and mRNA expression alteration of KRAS and cMYC in the 
TCGA pan cancer lung adenocarcinoma cohort, accessed through cBioportal. For mRNA analysis, Z 
score threshold was set to 1.5. Horizontal black lines indicate cases with alteration of both KRAS and 
MYC. (B) Ectopic proliferation induced by CRE-dependent activation of Rosa26-lsl-MYC in airway 
epithelium evidenced by BrdU incorporation. Images are representative of at least 4 mice/genotype. 
Scale bar = 40 μm. (C) Overall tumour burden, defined as the percent of lung area occupied by tumour 
tissue, in mice bearing 1 (N = 9) or 2 (N = 11) R26-lsl-MYC combined with lsl-KRasG12D, compared with 
lsl-KRasG12D alone (N = 6), measured 6 weeks post induction (PI). Mean ± SEM shown. ** denotes p < 
0.01 (t-Test). (D) Adult mice (8–10weeks old) bearing the indicated conditional alleles were 
administered 1 × 107 pfu Adeno-CRE by intranasal installation and harvested at the indicated times 
PI. Micrographs show representative Hematoxylin and Eosin (H&E)-stained lung tissue. Scale bars = 
1mm (left panels) and 200 μm (right panels). (E) Age-matched lsl-KRasG12D mice were induced with 
the same pfu Adeno-CRE as (D) and tumour burden examined after 6 weeks. Scale bars = 1mm (top 
panel) and 200 μm (bottom panel). 
Table 1. Specific genes upregulated in pErkHigh KM tumour regions. Genes were selected based on 
evidence of overexpression and/or amplification in human non-small cell lung cancer (NSCLC). 
Range of RNA-SEQ read count values, normalised for total reads per sample, for the indicated genes. 
FC = fold change. FDR = false discovery rate. Amp = Amplified. OverEx = Overexpressed. For 
“Amplified in human NSCLC”: Y = yes (1–5%) with >5% and <1% where noted; N = No; SCC = 
squamous cell carcinoma where noted, otherwise adenocarcinoma or unclassified. For 
“Overexpressed in human NSCLC”: Y = Yes; N = No. 
Symbol Gene Name range p-ERK neg 
range 
p-ERK pos 
Mean 
FC FDR 
Amp in 
NSCLC 
OverEx in 
NSCLC 
Ereg Epiregulin 5–39 227–376 24.82 2.78e-13 Y Y 
Sox9 SRY-like containing gene 9 6–31 39–330 15.79 7.48e-04 Y Y 
Dlk1 Delta-like 1 homolog 63–400 341–2114 10.46 2.33e-26 Y(SCC) N 
B4galt6 
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, 6 
7–91 113–491 9.46 1.24e-03 Y(SCC) Y 
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Basp1 
Brain abundant, membrane 
attached signal protein 1 
0–66 89–307 9.03 1.31e-04 Y > 10% Y 
Itga2 Integrin alpha 2 49–185 185–1239 6.79 2.47e-11 <1% Y 
Cldn4 Claudin 4 7–49 64–117 6.11 1.16e-02 Y Y 
CD24a CD24a antigen 145–1040 1411–1580 5.94 1.4e-15 No data Y 
Slc38A1 
Solute carrier family 38, member 
1 
60–153 248–716 5.68 1.17e-11 Y Y 
Arntl2 
Aryl hydrocarbon receptor 
nuclear translocator-like 2 
15–59 44–156 4.54 4.9e-02 Y > 7% Y 
Dsc2 Desmocollin 14–148 62–302 4.43 4.51e-02 Y(SCC) Y 
Areg Amphiregulin 156–234 526–831 4.25 4.98e-11 Y Y 
S100a6 S100 calcium binding protein A6 115–215 234–1017 4.00 1.51e-07 Y > 14% Y 
Itgb4 Integrin beta 4 31–89 81–310 3.92 2.29e-02 Y Y 
Atp13a4 ATPase type 13A4 242–399 711–1002 3.92 3.03e-14 Y > 25% Y 
Kif23 Kinesin family member 23 151–359 313–994 3.76 8.81e-07 <1% Y 
Porcn Porcupine homolog 38–52 76–182 3.59 4.85e-03 <1% N 
Krt8 Keratin 8 67–380 489–699 3.57 1.87e-05 Y Y 
Vcam1 
Vascular cell adhesion molecule 
1 
11–133 75–442 3.57 3.59e-02 <1% N 
Krt18 Keratin 18 503–827 1192–1850 3.50 1.8e-11 Y Y 
Lamc2 Laminin gamma 2 457–677 1104–1825 3.48 2.56e-09 Y > 7% Y 
Tnfrsf12a 
Tumour necrosis factor receptor 
superfamily, 12a 
30–54 86–135 3.42 1.47e-02 Y Y 
Tspan8 Tetraspanin 8 329–570 635–1848 3.41 5.23e-06 Y > 5% Y 
Atp6v1g3 
ATPase H+ transporting, 
lysosomal V1 subunit g3 
46–94 91–232 3.40 2.8e-03 Y > 7% N 
Ecm1 Extracellular matrix protein 1 44–79 100–173 3.25 7.13e-03 Y > 16% Y 
S100a14 
S100 calcium binding protein 
A14 
89–210 218-530 3.18 6.52e-04 Y > 14% Y 
Lgals3bp 
Lectin, galactoside-binding, 
soluble, 3 binding protein 
178–333 472–679 3.16 2.09e-05 Y Y 
Nt5e 5’ nucleotidase, ecto 148–339 462–697 3.04 1.2e-05 Y(SCC) Y 
Lad1 Ladinin 1 141–344 401–619 3.01 2.92e-05 Y > 7% Y 
Igfbp5 
Insulin-like growth factor 
binding protein 5 
296–422 414–1197 2.99 1.36e-05 <1% Y 
Pdia4 
Protein disulphide isomerase 
associated 4 
966–1887 2519–3183 2.98 3.16e-05 Y Y 
CD38 CD38 antigen 37–64 77–167 2.97 3.82e-02 <1% Y 
Krt19 Keratin 19 203–469 664–969 2.96 2.06e-06 <1% Y 
Slc2a1 
Solute carrier family 2, member 
1 
57–114 125–249 2.95 1.11e-02 Y Y 
Myrf Myelin regulatory factor 57–163 95–474 2.92 1.26e-02 <1% Y 
Plekha6 
Pleckstrin homology domain 
containing, family A , 6 
185–353 490–692 2.91 3.34e-05 <1% Y 
Ndrg1 
N-MYC downstream regulated 
gene 1 
77–333 208–716 2.84 7.71e-03 Y > 5% Y 
Rabgap1l 
RAB GTPase activating protein 
1-like 
1211–1754 2578–4099 2.83 3.95e-05 Y > 8% N 
Phlda1 
Pleckstrin homology-like 
domain family A, member 1 
105–226 175–402 2.82 7.01e-04 <1% Y 
Gapdh 
Glyceraldehyde-3-phosphate 
dehydrogenase 
79–106 136–216 2.80 1.08e-02 Y(SCC) Y 
Fabp5 
Fatty acid binding protein 5, 
epidermal 
78-175 115–410 2.79 6.15e-03 Y Y 
Cmas 
Cytidine monophospho-N-
acetylneuraminic acid 
synthetase 
49–106 108–283 2.75 4.21e-02 Y > 5% Y 
Golm1 Golgi membrane protein 1 509–1420 1343–2171 2.75 3.84e-05 N Y 
Ptges Prostaglandin E synthase 158–286 158–286 2.73 5.26e-03 Y Y 
Stk39 Serine/threonine kinase 39 304–659 872–1127 2.71 2.21e-06 Y Y 
Fam3c 
Family with sequence similarity 
3, member C 
351–642 673–1078 2.65 6.4e-09 Y N 
Pgk1 Phosphoglycerate kinase 1 138–178 220–425 2.61 1.23e-03 <1% Y 
Cacnb3 
Calcium channel, voltage 
dependent, beta 3 
56–87 78–147 2.59 3.7e-02 Y N 
Tnfrsf21 
Tumour necrosis factor receptor 
superfamily, 21 
121–238 232–348 2.57 1.58e-03 Y Y 
Fmo1 
Flavin containing 
monooxygenase 1 
174–256 186–1098 2.57 7.51e-03 Y > 7% Y 
Cancers 2019, 11, 600 6 of 14 
 
S100a11 
S100 calcium binding protein 
A11 
245–696 594–1252 2.53 1.21e-04 Y > 15% Y 
Ceacam1 
Carcinoembryonic antigen-
related cell adhesion molecule 1 
326–608 648–1286 2.50 1.08e-05 Y Y 
2.3. Functional Validation of p-Erk Associated Genes: Contribution to Cell Propagation 
We assembled a focused library of four separate siRNAs targeting each of the 52 p-ErkHI-
associated genes implicated in human non-small cell lung cancer (NSCLC) and confirmed the efficacy 
of targeted depletion of a randomly chosen subset in A549 cells using Quantitative-PCR (Figure S4A). 
We then screened the effect of each siRNA individually for the ability to suppress propagation of 3 
KRAS-mutated human NSCLC cell lines, A549 (G12S), H2009 (G12A), and H460 (Q61H). Cells were 
reverse transfected with individual siRNAs at low density and allowed to propagate for up to 72 h, 
whereupon, cell numbers were measured by high-content microscopy. Each screen included positive 
(Allstars, Qiagen, Hilden, Germany) and negative (non-targeting siRNA) controls. The effect of each 
individual siRNA on cell propagation was calculated as percent suppression of viability (SoV), 
relative to non-targeting siRNA-transfected cells, in each of the three cell lines. The mean SoV of all 
siRNAs across the entire dataset (M) was calculated for each cell line and used to set a threshold for 
acceptance or rejection of the effects of individual siRNAs: siRNAs that resulted in SoV > M were, 
thus, scored “positive”. Figure 2A summarizes the results of this analysis: siRNAs yielding greater 
than average SoV in all three cell lines are indicated by red bars; those that scored positive in 2/3 cell 
lines by yellow bars. Thus, for each FMO1, KIF23, KRT19, and SLC2A1, the same three out of four 
siRNAs consistently suppressed cell propagation in all three human NSCLC lines tested (Figure S4B) 
allowing us to say with confidence that these four genes are required to sustain proliferation of KRAS 
mutant human NSCLC cells. The functional requirement of nascent lung tumours for Kif23 has 
moreover been verified in vivo [27]. 
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Figure 2. Validation of KM tumour progression signature genes in human cell lines.(A) 
Summary of suppression of viability (SoV) screening data using four individual siRNAs to target each 
indicated gene in A549, H460, and H2009 cells. Red bars indicate greater than average SoV in all three 
cell lines; Yellow bars indicate greater than average SoV in 2/3 lines. (B) Mean (±SD) SoV of three 
siRNAs, targeting each of the indicated transcripts, that exhibit consistent effects in all three cell lines. 
(C) Suppression of H2009 (y-axis) and A549 (x-axis) cell migration upon depletion of gene products 
listed in (A). Top panel: Mean distance migrated (defined as percent “wound” closure) after separate 
transfection with four siRNAs targeting each gene. Lower panel: Mean migration distance values for 
siRNAs falling within one standard deviation of the mean of all four for each targeted gene. (D) 
Representative photomicrographs showing suppression of cell migration upon depletion of Wnt 
pathway component SOX9. Compare with GAPDH (top panels). (E) Pharmacological suppression of 
Wnt signalling using the PORCN inhibitor LGK974 suppresses migration of A549 cells, as determined 
by Incucyte time-lapse microscopy. Error bars show SD of technical triplicates. p value from t-Test 
shown. All data are representative of three or more experiments. 
2.4. Functional Validation of p-Erk Associated Genes: WNT Signalling Contributes to Cell Motility.  
Given the association of the dataset with an invasive phenotype [23] we used our focused siRNA 
library to ask if any of the selected genes affect migration of human NSCLC cells. RNAi reverse 
transfected A549 or H2009 cells were seeded in 96-well plates and grown to confluency over 48 h. 
Monolayers were then scratch ‘wounded’ with a woundmaker tool and monitored by Incucyte time-
lapse video microscopy until the scratch wounds of control siRNA-transfected cells were circa 90% 
closed. Total cell number per well was determined at the end of each experiment to assess the 
potential influence of loss of viability (LoV) upon the migration assay. The mean wound closure and 
LoV values were determined for each siRNA and averaged across all four siRNAs for each gene. 
Figure S2B shows the mean migration data plotted against the mean LoV for each gene for A549 and 
H2009 cells (H460 cells were omitted from this analysis as they failed to migrate under the conditions 
tested). Only in the case of KIF23 depletion was LoV found to consistently account for the observed 
suppression of scratch wound closure. Depletion of LAMC2, previously validated as required for 
invasion and metastasis in NSCLC [28], consistently suppressed migration in both cell lines. 
Interestingly, depletion of WNT signalling components, SOX9 or PORCN [29], also suppressed 
migration in both cell lines (Figure 2C, D), suggesting that WNT signalling contributes to NSCLC 
tumour progression beyond its ability to suppress senescence [30–32]. This effect was confirmed in 
A549 cells by pharmacological inhibition of PORCN (Figure 2E). 
2.5. Relevance of the Murine Dataset for Human Pulmonary Adenocarcinoma 
We used an online Kaplan Meier meta-analysis tool [28] to investigate the association of each of 
the 52 selected genes with overall survival (OS) and responsiveness to radio- or chemotherapy among 
human lung cancer patients. Cox regression plots of patient survival were generated based on a 
median split of gene expression levels above (High) or below (Low) median gene expression. 
Differential expression of 33 of the 52 genes is associated with significantly altered OS across all lung 
cancers (N = 1926), with high expression of 25 genes associated with significantly decreased OS 
(logrank p < 0.05). Upon analysis of histological subtypes, 35 genes are associated with significantly 
altered OS of adenocarcinoma patients (N = 719), with 28 genes overlapping with those significantly 
altered across all lung tumours. In contrast, only three genes (KRT8, KRT18, and GAPDH) correlate 
with significantly reduced OS of squamous cell carcinoma patients (N = 525), mirroring the 
histological classification of the murine KM tumours as adenocarcinoma (Figure 3A). Strikingly, high 
expression of SLC2A1, encoding the glucose transporter GLUT1, and the glycolytic genes GAPDH 
and PGK1, were associated with strongly reduced OS, particularly in the adenocarcinoma subtype 
(Figure 3B), consistent with the prognostic value of FDG-PET in LuAd [29]. 
Across all lung cancers, high expression of five of the 52 genes is associated with significantly 
worse outcome in patients who received chemotherapy (N = 176): SLC2A1, S100A11, GAPDH, FABP5, 
and ARNTL2. The latter two are also associated with worse outcomes in patients who received 
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radiotherapy (N = 70), with hazard ratios of 2.34 and 3.25, respectively. High expression of a further 
four genes is also associated with poorer response to radiotherapy: S100A14, PHLDA1, EREG, and 
CD24 (HRs ranging from 1.89 to 1.93). In contrast, high IGFBP5 expression is associated with a better 
outcome in patients who received radiotherapy (HR = 0.56) while high CEACAM1 expression is 
associated with a better outcome in patients who received chemotherapy (HR = 0.57). Expression of 
ERBB ligands EREG and AREG previously led us to identify an unexpected requirement for signalling 
through the ERBB family of receptor tyrosine kinases for development, progression, and maintenance 
of KRAS driven LuAd, verified independently by a second group [24,30]. Notably, high expression 
of either ERBB2 or ERBB3 is associated with resistance of adenocarcinoma to chemotherapy, although 
these data should be interpreted with caution due to the low sample sizes available (Figure 3C). The 
KM2 mouse model, thus, exposes a number of genes that have a meaningful impact on the overall 
survival and response to therapy of human lung adenocarcinoma, attesting to its value as a model 
for this disease in humans. 
 
Figure 3. Relevance of the KM tumour progression signature for overall survival of human LuAd 
patients. (A) Hazard ratios (HRs) of lung cancer patient overall survival associated with high 
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expression of genes listed in Table 1, determined on the basis of above-versus-below median gene 
expression, using the KMplot survival analysis portal. Analysis shows statistically significant HRs for 
all lung patients included (N = 1926), those with denocarcinoma (Adeno; N = 866), squamous cell 
carcinoma (Squamous; N = 675), and patients who received either chemotherapy (N = 178) or 
radiotherapy (N = 73). N.S. = Not statistically significant. (B) Overall survival plots based on above 
(red lines) versus below (black lines) median expression of glycolysis pathway genes in human lung 
adenocarcinoma (left panels) compared with lung squamous cell carcinoma (right panels). HR = 
hazard ratio. 95% confidence intervals shown in parenthesis. For the adenocarcinoma subtype, N = 
866; for the squamous subtype, N = 675. (C) High expression of ERBB2 and ERBB3 is associated with 
worse outcome in human adenocarcinoma patients receiving standard chemotherapy. Note that the 
low sample size available for this subgroup (N = 36) require that the data be considered preliminary. 
Right panel: High expression of the ERBB ligand EREG is associated with worse outcome for lung 
cancer patients receiving radiotherapy (N = 73). Low sample size precluded analysis of histological 
subtypes. 
3. Discussion 
We previously identified a gene signature associated with sporadic progression to locally 
invasive adenocarcinoma in a GEMM of lung cancer driven by endogenously expressed KRasG12D 
combined with modestly overexpressed c-MYC [24]. Systematic analysis of each individual gene in 
this signature in multiple human NSCLC cell lines has identified conserved requirements for cell 
proliferation and identified a key role for WNT signalling in NSCLC cell migration. Crucially, 
analysis of human lung cancer patient survival data demonstrates that the KM2 progression signature 
encompasses many genes that are significantly and specifically associated with the overall survival 
of lung adenocarcinoma patients. It should be noted that the patient survival analysis made no 
reference to KRAS mutation status and, thus, includes patient with EGFR, ALK, and other undefined 
driver mutations. The nevertheless strong association of the signature with the adenocarcinoma 
subtype may, thus, reflect general properties of LuAd tumour progression, irrespective of the driver 
oncogenes present. Alternatively, further stratification by driver oncogene may enhance some of 
these associations. Intriguingly, several signature genes are associated with differential survival of 
patients treated with chemotherapy versus radiotherapy. Further validation of such genes may, in 
future, help guide selective treatment strategies for LuAd.  
The KM2 spontaneous progression signature highlights the specific impact of the glycolytic 
cascade on patient survival: Elevated expression of the glucose transporter SLC2A1 and glycolytic 
enzymes GAPDGH and PGK1 are associated with profoundly lower overall survival of 
denocarcinoma patients, with more modest associations in the squamous cell subtype. Increased 
glycolytic activity linked to tumour progression was also observed in an independent GEMM model 
and correlated with the amplification of the active KRasG12D allele [31]. As well as being processed for 
ATP consumption and macromolecular synthesis, much glucose uptake is diverted via the pentose 
phosphate and 1-carbon pathways for maintenance of cellular anti-oxidant capacity [32]. Although 
not included in our progression-associated gene signature, we found increased expression of many 
anti-oxidant genes as KM2 tumour progress to invasive disease. The clinical relevance of anti-oxidant 
gene expression in LuAd is a reflected loss of function mutations in KEAP1, which suppresses anti-
oxidant gene expression, in some 20% of cases. Genetic deletion of Keap1 or overexpression of its 
target, the anti-oxidant master regulatory transcription factor NRF2, accelerates KRas-driven LuAd 
in mice, suggesting that excessive oxidative stress limits tumour progression [33,34]. Targeted 
suppression of the anti-oxidant pathway may, thus, expose lung tumours to excessive oxidative 
stress, leading to improved therapeutic outcomes [35]. 
Along the same lines, the KM2 progression signature led us to identify an unexpected 
requirement for signalling through the ERBB family of receptor tyrosine kinases upstream of KRAS, 
despite the presence of the G12D activating mutation [24]. ERBB family proteins have proven to be 
far more amenable to pharmacological inhibition than KRAS itself, and multiple ERBB inhibitors are 
approved for the treatment of cancers expressing mutant or amplified ERBB isoforms. Indeed, we 
and others have demonstrated the efficacy of broad-spectrum ERBB inhibitors against KRAS driven 
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LuAd in vitro and in vivo [24,30,36]. To this we now add patient survival data associated with 
overexpression of ERBB receptors and ligands, suggesting that elevated activity of this pathway may 
strongly influence responses to standard-of-care therapies. It is important to note that considerable 
redundancy exists within the ERBB network, between four receptors that can all homo- or hetero-
dimerise upon binding of to up to 10 or more ligands. As such, broad specificity inhibition of all four 
RTKs may be more desirable than selective inhibition of any one [37]. 
The KM2 model, thus, recapitulates multiple salient molecular features with clear clinical 
relevance for human lung adenocarcinoma. Data presented here represent the analysis of the earliest 
detectable spontaneous progression of KM2 tumours to invasive heterogeneous disease, and it is 
worth noting that tumour heterogeneity increases along with the emergence of metastases upon 
longer incubation [24]. The model, thus, allows incipient tumours to evolve sporadically, driven by 
emerging selective pressures rather than by the immediate consequence of transgene expression. 
Allowing autochthonous tumours to evolve in this manner likely exposes them to many of the same 
physiological barriers encountered by incipient human tumours, despite the complete absence of 
environmental toxins in the GEMM system, and this is reflected in the tumour progression signature. 
We believe that the KM2 model is, thus, an excellent system for further investigation of lung tumour 
evolution and for pre-clinical evaluation of new therapeutic strategies. 
4. Materials and Methods 
4.1. Genetically Engineered Mice and Mouse Procedures 
Procedures involving mice were performed in accordance with protocol numbers 55.2-2531.01-
72/10 (University of Würzburg, Würzburg, Germany) and Home Office licence numbers 60/4183 and 
70/7950 (CRUK BICR, Glasgow, UK). Rosa26DM.lsl-MYC mice were generated as previously described 
[24] using vectors described in [38]: Targeted insertion into the Rosa26 locus was confirmed by 
Southern blotting, and genotyping was performed using the following primers: A) CCC AAA GTC 
GCT CTG AGT TG (common); B) GCG AAG AGT TTG TCC TCA ACC (targeted locus); C) GGA 
GCG GGA GAA ATG GAT ATG A (wild-type locus). All genotyping was subsequently performed 
by Transnetyx Inc. Lsl-KRasG12D [5] mice were obtained from the NCI (US National Cancer Institute) 
mouse repository at Fredrick, MD, USA. Mice were maintained on a mixed FVBN/C57Bl6 
background, housed on a 12 h light/dark cycle and fed and watered ad libitum. Both males and 
females were included in the study. Recombinant adenovirus expressing CRE was purchased from 
the University of Iowa gene therapy core facility. For Adeno-Cre installation, mice aged 8 weeks were 
sedated with a mixture of domitor and ketamine, injected IP. For most experiments, 1x107 pfu Adeno-
CRE were administered intranasally using the calcium phosphate precipitation method, as described 
previously [17]. BrdU injection was performed at least 2 h prior to sacrifice. All mice were sacrificed 
using a schedule 1 procedure. Rosa26DM.lsl-MYC mice are available upon request from D.J.M. 
4.2. Immunohistochemistry and Tissue Analysis 
Mouse tissues were perfused with zinc formalin overnight. Four micrometer paraffin sections 
were de-paraffinized and rehydrated: 3 × 5 minutes xylene, 2 min in each 2 × 100%; 2 × 95%; 2 × 70%; 
1 × 50% ethanol; dH2O. Peroxidase blocking was performed for 10 min in 3% H2O2 diluted in H2O, 
followed by antigen retrieval in 10 mM citrate buffer, pH 6, 10 min near boiling by microwave heating 
at low power. Non-specific antibody binding was blocked with up to 3% BSA or up to 5% normal 
goat serum for 1 h at RT or overnight at 4 °C. Primary antibody incubation was performed overnight 
at 4 °C or 2 h at 37 °C. Secondary biotinylated antibody was incubated 1 h at room temperature, and 
stain was developed with stable DAB (Diaminobanzadine, Invitrogen, Carlsbad, CA, USA) followed 
by counterstaining with Gil 1 hematoxylin (MH216, Sigma Chemicals, St. Louis, MI, USA) and Scotts 
tap water substitute. The following antibodies were used at the indicated dilution: p-Erk (P44/42 
MAPK phosphor-Thr202/Tyr204), Cell Signalling CS4370, BrdU, Serotec OBT0030CX, 1:250 or BD 
Biosciences 347580 1:200; Vectorlabs VECTASTAIN ABC kit; anti-Rabbit IgG (immunoglobulin G), 
PK-4001 ECL (enhanced chemoluminescence reagent); anti Rat, GE Healthcare NA935. Tumour 
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burden was determined using Leica software as the percentage area of lung tissue occupied by 
tumours, measured on three Hematoxylin and Eosin (H&E) stained sections, separated by at least 
100 μm, from each of the indicated numbers of mice. Histological classification of tumours as 
adenocarcinoma was determined by a clinical pathologist. Laser-capture and RNA-SEQ analysis 
were performed as previously described [24]. RNA-SEQ data are available from Arrayexpress: E-
MTAB 6432. 
4.3. Cell Culture and Related Assays  
Established lung cancer cell lines (A549, H2009, H460) were validated in-house and grown in 
DMEM (Dulbecco’s modified Eagle medium) with 10% FBS and penn/strep. A focused de-convoluted 
library of 4 siRNAs targeting each of 51 selected gene products was purchased from Qiagen. For 
analysis of cell viability, cells were reverse transfected with individual siRNAs in 96-well plates at a 
density that yielded 70% confluence after 72 h incubation when transfected with non-targeting 
control siRNA. Cells were transfected with each siRNA in technical quadruplicate, using either 
Lipofectamine 2000 or RNAi Max, after optimization of transfection for each cell line. Seventy-two 
hours later, cells were washed with PBS (phosphate-buffered saline), fixed with 4% PFA 
(paraformaldehyde) for 20 min, stained with DAPI (4′,6-diamidino-2-phenylindole) and nuclei were 
counted using Columbus Image Analysis following image acquisition on an Operetta High Content 
Analyzer. Screening was performed in triplicate for each cell line. To measure effects on cell 
migration, cells were reverse transfected in 96-well plates at a density that yielded 100% confluence 
after 48 h when transfected with non-targeting siRNA. After 48 h, scratch wounds were made using 
a 96-point woundmaker tool. Scratch wounds were measured by Incucyte time-lapse video 
microscopy for up to 46 h (A549) or 20 h (H2009) after wounding. Cells were then fixed and DAPI-
stained nuclei counted by Operetta. Migration screens were performed in triplicate for each cell line. 
4.4. Statistical Analysis 
Analysis was performed as previously reported [24]: Raw data obtained from quantitative real 
time PCR (polymerase chain reaction), FACS (fluorescence activated cell sorting), siRNA (small 
inhibitory ribonucleic acid) screening and Incucyte assays were copied into Excel (Microsoft, 
Redmond, WA, USA) spreadsheets. All Mean values, SD, and SEM values of biological replicates 
were calculated using the calculator function. Graphical representation of such data was also 
produced in Excel (Microsoft). Statistical significance for pairwise data was determined by the 
Student’s t-Test. For multiple comparisons, ANOVA was used with a post-hoc Turkey test. * denotes 
p < 0.05; ** denotes p < 0.01; *** denotes p < 0.005. For analysis of human survival data, univariate Cox 
regression plots to assess the association of individual genes with lung cancer patient overall survival 
were plotted using KMplot.com [28] with a median patient split. Where multiple probes were 
available for a single gene, the median hazard ratio is presented. p values from Logrank tests are 
provided. 
5. Conclusions 
A gene expression signature associated with spontaneous progression of murine lung tumours 
driven by the combination KRasG12D and modest overexpression of MYC identified multiple genes 
required for viability and/or cell migration of KRAS mutant human lung tumour cells. In vitro 
validation of individual genes exposed an unexpected requirement for Wnt signalling in cell 
migration. Analysis of human lung cancer patient survival revealed the significant prognostic 
association of individual genes, specifically for the adenocarcinoma subtype, along with several 
potential predictors of patient responses to standard chemo or radiotherapy. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/11/5/600/s1: 
Figure S1: Generation of Rosa26DM.lsl-MYC mice. Figure S2: Statistical analysis of KRAS and MYC alterations in 
human LuAd. Figure S3: High-resolution images of K-only and KM2 tumour histology. Figure S4: In vitro 
validation of KM2 LuAd progression signature genes.  
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